导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.67% | 3263/4773 |
| 近一周 | -2.34% | 3743/5465 |
| 近一月 | -1.79% | 1303/5421 |
| 近一季 | -3.82% | 1695/5231 |
| 近半年 | -7.36% | 3327/4920 |
| 近一年 | -6.70% | 3220/4394 |
| 近两年 | 40.06% | 1894/2954 |
| 近三年 | 21.09% | 1445/2253 |
| 成立以来 | 38.38% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.24% 2198/4961 |
-1.60% 3357/5312 |
- - |
- - |
| 2025 | 16.00% 2499/4813 |
3.30% 1123/3635 |
9.06% 302/4076 |
5.08% 3610/4524 |
-2.01% 3062/4813 |
| 2024 | 16.80% 764/3463 |
4.64% 442/2808 |
-2.86% 1267/3014 |
13.68% 2133/3129 |
1.08% 1123/3463 |
| 2023 | -3.02% 622/2656 |
2.42% 1354/2280 |
2.56% 132/2385 |
-1.87% 592/2515 |
-5.92% 1558/2655 |
| 2022 | -12.86% 303/2207 |
-9.89% 363/1919 |
1.70% 1436/2016 |
-10.25% 368/2113 |
5.96% 407/2208 |
| 2021 | 12.72% 377/1822 |
3.96% 163/1255 |
9.05% 589/1330 |
-5.01% 763/1466 |
4.67% 320/1822 |
| 2020 | - - |
- - |
- - |
- - |
2.68% 974/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏中证浙江国资创新发展ETF联接A VS. 长安沪深300非周期A(740101) |